体外研究
HTHQ (0-100 μM; 24 hours; PC12 cells) treatment increases cell viabilities in a dose-dependent manner. HTHQ (10 μM; 0.6-24 hours; PC12 cells) inhibits 3,4-L-Dihydroxyphenylalanine (L-DOPA) -induced phosphorylation of sustaines extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). HTHQ also normalizes L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression, promoting cell survival. Cell Viability Assay Cell Line: PC12 cells Concentration: 0 μM, 1 μM, 10 μM, and 100 μM Incubation Time: 24 hours Result: Reduced cell viability at 24 hours caused by both 100 and 200 µM L-DOPA was significantly attenuated. Western Blot Analysis Cell Line: PC12 cells Concentration: 10 μM Incubation Time: 0.6-24 hours Result: Inhibited L-DOPA-induced phosphorylation of sustained extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). And also normalized L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression.